AI
Saturday, January 31, 2009 9:53:18 AM
Genasense: "It ain't over till the fat lady sings"
That's all you get unless you register. What I noticed was towards the end where the FDA gave the reason for non-approval as testing bias. That's why Genta is now conducting the AGENDA Phase III Trial. The Agenda trial is a DOUBLE-BLIND, PLACEBO study that's being conducted around the world. There is simply no way the FDA can use the same excuse this time around, and to cap it all off, this double-blind study is producing even better confirmatory and efficacy data.
We got a winner, guys.
That's all you get unless you register. What I noticed was towards the end where the FDA gave the reason for non-approval as testing bias. That's why Genta is now conducting the AGENDA Phase III Trial. The Agenda trial is a DOUBLE-BLIND, PLACEBO study that's being conducted around the world. There is simply no way the FDA can use the same excuse this time around, and to cap it all off, this double-blind study is producing even better confirmatory and efficacy data.
We got a winner, guys.
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
